{"analyses":[{"ciLowerLimit":"0.56","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.34","estimateComment":"Reference level = non-variant","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2571","pValueComment":"One-sided significance level = 0.025.","paramType":"Cox Proportional Hazard","paramValue":"0.87","statisticalComment":"Stratified by treatment arm.","statisticalMethod":"Regression, Cox"}],"anticipatedPostingDate":"2025-12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72.3","upperLimit":"88.9","value":"80.6"},{"groupId":"OG001","lowerLimit":"75.4","upperLimit":"83.0","value":"79.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"470"}],"units":"Participants"}],"description":"KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is a gene that helps control how cells grow. Some people have a change in this gene, which can be detected (variant/non-variant) by a genetic test performed on tissue from their tumor. Research suggests that this change may influence how head and neck cancer responds to certain treatments.\n\nAn event for overall survival is death due to any cause. Survival time is defined as time from randomization to the date of death or last known follow-up (censored). Rates are estimated by the Kaplan-Meier method. The protocol endpoint is hazard ratio, which is reported in the statistical analysis results. Five-year rate is reported simply as summary data; it is not the outcome measure.","dispersionType":"95% Confidence Interval","groups":[{"description":"Has the KRAS variant","id":"OG000","title":"Variant"},{"description":"Does not have the KRAS variant","id":"OG001","title":"Non-variant"}],"paramType":"NUMBER","populationDescription":"Eligible participants with KRAS data","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Analysis was to occur after 180 deaths were reported. Analysis occurred after 214 deaths were reported. Median follow-up at time of analysis was 8.3 years.","title":"Overall Survival by KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) Variant Status","type":"SECONDARY","unitOfMeasure":"percentage of participants"}